Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?February 07, 2017
Investigators report on their findings from preclinical studies of luteolin injections to prevent lung metastases of triple-negative breast cancer.
CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast
Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast CancerJune 03, 2016
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase InhibitorsJune 03, 2016
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
The geometric shape of the outside edge of a cancerous tumor plays a significant role in activating tumor-seeding cells that lead to metastasis.
A low-dose of aspirin could increase survival by up to 20% and help stop metastasis for patients receiving cancer treatment.
A small, phase I clinical trial indicates the experimental drug guadecitabine is safe in combination with the chemotherapy drug irinotecan, and it may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.
Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.
Adding radiotherapy to chemotherapy and surgery reduced the number of local disease recurrences but did not affect distant recurrences or survival.
Cancer metastasis is dynamically regulated by cancer-associated fibroblasts (CAFs), a cancer-promoting component in the tumor microenvironment. Eliminating the CAFs after 10 days dramatically increases the risk of the primary tumor metastasis to the lungs and bones in a mouse model.
Current sequencing technology has enabled an analysis of cancer evolution that directs research attention away from the search for genes that enable metastasis and toward genes that are mutated early during tumorigenesis.
A gene previously thought only to be expressed in the brain, GABAA receptor alpha3 (Gabra3), promotes breast cancer migration, invasion, and metastasis.
PRAME mRNA expression is independent prognostic biomarker in Class 1 uveal melanoma.
The protein EPHA2, a receptor on the lining of blood vessels, controls how breast cancer cells metastasize around the body. These findings shed light on how cancer cells exit blood vessels to enter a new part of the body.
Researchers visualized the origins of cancer from the first affected cell through its spread in a live animal: the zebrafish. This research may change scientific understanding of melanoma and other cancers leading to new treatments that can be administered before the cancer has taken hold.
No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
Circulating Tumor DNA More Effective Than LDH at Detecting Metastatic Melanoma Progression, RecurrenceJanuary 25, 2016
Metastatic melanoma disease activity may be monitored via circulating tumor DNA, which has higher sensitivity than lactate dehydrogenase for detecting disease progression.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
High amounts of dietary sugar, as is common in the typical Western diet, may increase the risk of breast cancer and metastasis to the lungs.
Obesity potently increases the potential for metastasis of ovarian cancer. A large number of studies have shown that higher body mass index is associated with a greater risk for ovarian cancer with worse overall survival.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
The size of a surgically removed tumor is generally thought to relate to the risk of metastasis; however, tumor cells metastasize at different times therefore the rate of spread is difficult to assess. A mathematical model was developed to calculate the relationship between tumor size and the relative risk of recurrence after surgery.
Researchers developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting, and surfing the Web.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|